Indoor Biotechnologies, Inc.http://www.inbio.com
- Founded: 1997
- CEO: Martin D. Chapman, PhD
- Size of Facility: 13200 sq ft
- Company Size: 20
- Funding Source: Grants (e.g. SBIR, CRCF, CIT), Privately Held
- Development Stage: Not Applicable
Indoor Biotechnologies specializes in manufacturing biologics for allergy and asthma. The company is recognized as the world leader in assessment of environmental exposure to allergens – in the home, workplace, schools and commercial buildings. The company manufactures highly purified allergens for allergy research and diagnostics, and is internationally recognized for research on allergen structure, function and immune recognition. Indoor Biotechnologies mission is to improve the quality of life of patients with allergy and asthma. Indoor Biotechnologies has affiliated companies in Cardiff, Wales, UK and in Bengalaru, India, together with distributors in Japan, China and Korea.